Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03051100 · ClinicalTrials.gov registry record · Phase 2
Evaluation of the Efficacy and Safety of Bempedoic Acid (ETC-1002) 180mg, Ezetimibe 10mg, and Atorvastatin 20 mg Triplet Therapy in Patients With Elevated LDL-C
A Phase 2 study of Hypercholesterolemia, sponsored by Esperion Therapeutics.
- Completed
- Registry status
- Phase 2
- Development phase
- 63
- Enrollment target
- 11
- Study locations
NCT03051100 is a Phase 2 study of Hypercholesterolemia that has completed, run by Esperion Therapeutics. The registered enrollment target is 63 participants, below the 816-participant average among 62 other Hypercholesterolemia trials with a reported enrollment target (92% lower). The trial reports 11 study locations across 4 states.
The verdict
NCT03051100, a Phase 2 study of Hypercholesterolemia, has completed, sponsored by Esperion Therapeutics.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 63 participants
- Enrollment target
- 11
- Study locations
Study Summary
The purpose of this study is to determine if triplet therapy with bempedoic acid (ETC-1002) 180mg, ezetimibe 10mg, and atorvastatin 20mg is effective and safe versus placebo in patients with elevated LDL cholesterol.
Conditions Studied
Interventions
- OTHER Placebo
- DRUG Atorvastatin 20mg
- DRUG Bempedoic acid 180mg
- DRUG Ezetimibe 10mg
Study Locations (11)
North Carolina
- PMG Research of Cary - Cary
- PMG Research of Charlotte - Charlotte
- Sensenbrenner Primary Care - Charlotte
- PMG Research of Hickory - Hickory
- PMG Research of Raleigh - Raleigh
- PMG Research of Rocky Mount - Rocky Mount
- PMG Research Salisbury - Salisbury
- PMG Research of Wilmington - Wilmington
Illinois
- PMG Research of Christie Clinic - Champaign
South Carolina
- PMG Research of Charleston - Mt. Pleasant
Virginia
- Hampton Roads Center for Clinical Research - Virginia Beach
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 63 participants |
| Start Date | 2017-01-19 |
| Est. Completion | 2017-07-05 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03051100
The ClinicalTrials.gov registry entry for NCT03051100 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 63 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 816-participant average among 62 other Hypercholesterolemia trials with a reported enrollment target (92% lower). The listed sponsor is Esperion Therapeutics, which has 23 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Hypercholesterolemia appearing as the primary indexed condition, and to 4 interventions - of which Placebo is the first listed.
NCT03051100 reports 11 study locations spanning 4 distinct geographic areas - top geographies include North Carolina, Illinois, South Carolina.
Frequently Asked Questions
What is clinical trial NCT03051100 about?
NCT03051100 is a clinical study titled "Evaluation of the Efficacy and Safety of Bempedoic Acid (ETC-1002) 180mg, Ezetimibe 10mg, and Atorvastatin 20 mg Triplet Therapy in Patients With Elevated LDL-C". The purpose of this study is to determine if triplet therapy with bempedoic acid (ETC-1002) 180mg, ezetimibe 10mg, and atorvastatin 20mg is effective and safe versus placebo in patients with elevated LDL cholesterol.
What is the current status of trial NCT03051100?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 63 participants. The study started on 2017-01-19. Estimated completion is 2017-07-05.
What conditions does trial NCT03051100 study?
This clinical trial studies the following conditions: Hypercholesterolemia.
What interventions are being tested in trial NCT03051100?
The interventions under investigation include: Placebo (OTHER), Atorvastatin 20mg (DRUG), Bempedoic acid 180mg (DRUG), Ezetimibe 10mg (DRUG).
Who is sponsoring clinical trial NCT03051100?
This trial is sponsored by Esperion Therapeutics, which has 23 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT03051100 being conducted?
This trial has 11 study locations across Illinois, North Carolina, South Carolina, Virginia. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Hypercholesterolemia
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Emergency Medicine Cardiovascular Risk Assessment for Lipid Disorders Trial
RECRUITING · Phase 2
-
The Safety & Efficacy of Combination BMS-201038 (AEGR-733) & Ezetimibe vs. Monotherapy in Moderate Hypercholesterolemia
COMPLETED · Phase 2
-
Open-Label Extension of Study R727-CL-1003 (NCT01266876) to Evaluate the Long-Term Safety and Efficacy of Alirocumab (REGN727) in Participants With Heterozygous Familial Hypercholesterolemia (HeFH)
COMPLETED · Phase 2
-
Evaluation of ETC-1002 in Participants With Hypercholesterolemia and Hypertension
COMPLETED · Phase 2
-
Pilot Study To Assess CAT-2003 in Patients With Hyperlipidemia
COMPLETED · Phase 2
-
Study of Oral MD-0727 Administered to Patients With Primary Hypercholesterolemia
COMPLETED · Phase 2
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.